CAR-T Therapy for Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) is a fast-growing cancer of the blood and bone marrow, characterized by the uncontrolled growth of immature white blood cells. AML is aggressive and often difficult to treat, especially when patients relapse or become resistant to standard therapies like chemotherapy or stem cell transplants. CAR-T (Chimeric Antigen Receptor T-cell) therapy is an innovative, cutting-edge approach that is bringing hope to patients with relapsed or refractory AML, offering a personalized and targeted solution when traditional treatments fail.

CAR-T therapy involves engineering a patient's own T-cells to better recognize and attack cancer cells. For AML, CAR-T cells are designed to target specific antigens expressed on the surface of leukemic cells, which are commonly found in AML cells. By reprogramming the patient's T-cells to identify and destroy these malignant cells, CAR-T therapy offers the potential for complete remission and long-term survival, even for patients with limited treatment options.

• High Efficacy for Relapsed and Refractory AML: CAR-T therapy has shown great promise in patients whose AML has returned or does not respond to traditional treatments.
• Targeted Treatment: By specifically targeting leukemia cells, CAR-T therapy minimizes damage to healthy cells, offering a more precise treatment compared to conventional therapies.
• Personalized and Innovative: CAR-T therapy is tailored to each patient, using their own T-cells for a highly individualized treatment plan, leading to a reduced risk of rejection.
• Potential for Long-Term Remission: Many patients have achieved long-lasting remissions and even complete eradication of leukemic cells after undergoing CAR-T therapy.

• T-cell Collection: The first step involves collecting T-cells from the patient's blood through a process called leukapheresis.
• Engineering the T-cells: The collected T-cells are then modified in the laboratory to express a receptor that targets AML-specific antigens like CD33 or CD123.
• Infusion of Modified T-cells: After expanding the engineered T-cells, they are infused back into the patient's bloodstream.
• Post-Treatment Monitoring and Recovery: Following the infusion, patients are closely monitored for side effects, such as cytokine release syndrome (CRS) or neurotoxicity, which can usually be managed with timely medical intervention.

• State-of-the-Art CAR-T Technology: BIOOCUS uses the latest advancements in CAR-T technology to offer patients the most effective and cutting-edge treatment options for AML.
• Expert Care Team: Our team of hematology specialists and immunotherapy experts work together to provide personalized care for each patient, ensuring the best possible outcomes.
• Proven Success in AML Treatment: We have successfully treated numerous patients with relapsed or refractory AML using CAR-T therapy, achieving significant improvements and remission.
• Comprehensive Support for International Patients: BIOOCUS provides complete support to international patients, including consultation, treatment, and post-treatment care, ensuring a smooth journey throughout the entire process.

• CAR-T therapy for AML has shown outstanding success in treating relapsed and refractory cases, with many patients experiencing significant clinical improvements. The following case studies demonstrate the transformative power of CAR-T therapy in AML treatment:

  • Patient Story: AML Survivor, 9 Years Post-Transplant—Embracing the Power of Hope and Rebirth
  • A Teen Reclaims Hope After AML Diagnosis—A Journey of Resilience and Recovery
  • Overcoming Acute Myeloid Leukemia and Rebirth After Stem Cell Transplant

  These real-life stories demonstrate the potential of CAR-T therapy to significantly improve patient outcomes and offer new hope for those battling AML. Patients have shown remarkable responses, including long-term remission and recovery, even after failing previous treatments.